


















Robert Narquizian and Jacqueline Milne






Department of Chemistry, University of Glasgow, Glasgow, UK G12 8QQ

Perkin 1 Abstracts: Natural Product Synthesis aims to highlight syntheses that have been recently published. It includes brief descriptions of *biological activity* and *key steps*. A more comprehensive list of Natural Product syntheses and isolations can be found in *Natural Product Updates*.

<p>5-N-Acetylardeemin and Amauromine</p> <p><i>Biological activity:</i> multidrug resistance reversal agents.</p> <p><i>Key steps:</i> (a) <i>N</i>-phenylselenophthalimide-induced phenyl selenocyclisation of a tryptophan derivative to generate the pyrrolo[2,3-<i>b</i>]indole system; (b) substitution of a phenylseleno group by a prenylstannane using methyl triflate activation.</p> <p>K. M. DePew, S. P. Marsden, D. Zatorska, A. Zatorski, W. G. Bornmann and S. J. Danishefsky, <i>J. Am. Chem. Soc.</i>, 1999, 121, 11953.</p>	 <p>5-N-Acetylardeemin Amauromine</p>
<p>(-)-Adociasulfate 1</p> <p><i>Biological activity:</i> kinensin motor protein inhibitor isolated from extracts of a sponge of the genus <i>Haliclona</i>.</p> <p><i>Key steps:</i> biomimetic tetracyclisation triggered by an epoxide and terminated by an arene triether.</p> <p>M. Bogenstätter, A. Limberg, L. E. Overman and A. L. Tomasi, <i>J. Am. Chem. Soc.</i>, 1999, 121, 12206.</p>	
<p>Aflatoxin M₂</p> <p><i>Biological activity:</i> potent carcinogen.</p> <p><i>Key steps:</i> addition of dichloromethylithium to a dihydroxy ketone.</p> <p>G. A. Kraus and X. Wang, <i>Tetrahedron Lett.</i>, 1999, 40, 8513.</p>	
<p>(±)-Akagerine and (±)-Geissoschizine</p> <p><i>Biological activity:</i> Geissoschizine is an intermediate in indole alkaloid biosynthesis.</p> <p><i>Key steps:</i> (a) nucleophilic addition of the enolate derived from 1-acetylindole to a pyridinium salt; (b) acid-induced cyclisation of a 1,4-dihydropyridine; (c) Pummerer reaction.</p> <p>M.-L. Bannasar, J.-M. Jiménez, B. Vidal, B. A. Sufi and J. Bosch, <i>J. Org. Chem.</i>, 1999, 64, 9605.</p>	 <p>Akagerine Geissoschizine</p>
<p>(+)-Azimic acid</p> <p><i>Biological activity:</i> not reported.</p> <p><i>Key steps:</i> chelation-controlled addition of Grignard reagents to chiral α-amino aldehydes.</p> <p>K. K. Kumar and A. Datta, <i>Tetrahedron</i>, 1999, 55, 13899.</p>	

<p>Batzelladine D</p> <p><i>Biological activity:</i> (a) Batzelladines A and B are micromolecular inhibitors of binding of the HIV envelope protein gp-120 to the human CD4 receptor; (b) Batzelladines F-I induce dissociation of the protein kinase called p56^{lck} from CD4; (c) biological activity of Batzelladine D is not reported.</p> <p><i>Key steps:</i> tethered Biginelli condensation of a guanidine aldehyde and an acetoacetic ester to generate a 7-substituted-1-iminohexahydropyrrolo-[1,2-<i>c</i>]pyrimidine intermediate having the <i>anti</i> stereochemistry of the methine hydrogens flanking the pyrrolidine nitrogen.</p> <p>F. Cohen, L. E. Overman and S. K. Ly Sakata, <i>Org. Lett.</i>, 1999, 1, 2169.</p>	
<p>Clavepictines A, B and Pictamine</p> <p><i>Biological activity:</i> inhibition of growth of murine leukaemia and human solid tumour cell lines (P-388, A-539, U-251 and SN12K1) at IC₅₀ = 1.8–8.5 μg mL⁻¹.</p> <p><i>Key steps:</i> stereocontrolled intramolecular Michael-type ring closure of a conformationally constrained piperidine ring system.</p> <p>N. Toyooka, Y. Yotsui, Y. Yoshida, T. Momose and H. Nemoto, <i>Tetrahedron</i>, 1999, 55, 15209.</p>	 <p>Clavepictine A: R=Ac n=3 Clavepictine B: R=H n=3 Pictamine: R=Ac n=1</p>
<p>(–)-Cytosaxone</p> <p><i>Biological activity:</i> cytokine-modulating activity due to the inhibition of the signaling pathway of Th2 cells.</p> <p><i>Key steps:</i> imino 1,2-Wittig rearrangement.</p> <p>O. Miyata, H. Asai and T. Naito, <i>Synlett</i>, 1999, 1915.</p>	
<p>Dammarenediol I and II</p> <p><i>Biological activity:</i> modest <i>in vitro</i> antiviral activity against <i>Herpes simplex</i>.</p> <p><i>Key steps:</i> nonenzymatic biomimetic polyene tetracyclisation of a substrate containing a tetramethylallylic alcohol initiator, an allyltrimethylsilane terminating group, and a fluorine atom to serve as a cation-stabilising (C-S) auxiliary controlling the stereochemistry of the C/D ring juncture.</p> <p>W. S. Johnson, W. R. Bartlett, B. A. Czeskis, A. Gautier, C. H. Lee, R. Lemoine, E. J. Leopold, G. R. Luedtke and K. J. Bancroft, <i>J. Org. Chem.</i>, 1999, 64, 9587.</p>	 <p>Dammarenediol I: X=OH, Y=Me Dammarenediol II: X=Me, Y=OH</p>
<p>Dihydroclerodin</p> <p><i>Biological activity:</i> insect-antifeedant.</p> <p><i>Key steps:</i> (a) Mukaiyama reaction; (b) catalytic hydrogenation of an enone; (c) Chugaev elimination to give an exocyclic double bond.</p> <p>T. M. Meulemans, G. A. Stork, F. Z. Macaev, B. J. M. Jansen and A. de Groot, <i>J. Org. Chem.</i>, 1999, 64, 9178.</p>	
<p>(+)-Discodermolide</p> <p><i>Biological activity:</i> (a) immunosuppressant; (b) stabilises microtubules and promotes polymerisation of tubulin.</p> <p><i>Key steps:</i> A 27 step synthesis based on boron-mediated <i>anti</i>-selective aldol reactions of chiral ketones.</p> <p>I. Paterson, G. J. Florence, K. Gerlach and J. P. Scott, <i>Angew. Chem., Int. Ed.</i>, 2000, 39, 377.</p>	

<p>3-O-Galloyl-(2R,3R)-epicatechin-4β,8-[3-O-galloyl-(2R,3R)-epicatechin</p> <p><i>Biological activity:</i> the target, a proanthocyanidin derivative found in cocoa, is a protein kinase C inhibitor and cancer cell growth inhibitor.</p> <p><i>Key steps:</i> (a) benzylic oxidation with DDQ in ethylene glycol introduces a 2-hydroxyethoxy group; (b) TiCl₄-induced arylation of a benzylic cation creates an epicatechin dimer.</p> <p>W. Tückmantel, A. P. Kozikowski and L. R. Romanczyk, <i>J. Am. Chem. Soc.</i>, 1999, 121, 12073.</p>	
<p>Gypsetin</p> <p><i>Biological activity:</i> inhibits acyl CoA:cholesterol acyltransferase.</p> <p><i>Key steps:</i> (a) addition of a prenylborane to a chloroindoline; (b) two-fold dimethyldioxirane-induced oxidative ring closure of a tryptophan-derived diketopiperazine derivative. Deoxybrevianamide, brevianamide E and tryprostatin B were also synthesised.</p> <p>J. M. Schkeryantz, J. C. G. Woo, P. Siliphaivanh, K. M. DePew and S. J. Danishefsky, <i>J. Am. Chem. Soc.</i>, 1999, 121, 11964.</p>	
<p>Jimenezin</p> <p><i>Biological activity:</i> (a) active against BST assay (IC₅₀ = 5.7 ng mL⁻¹); (b) potent cytotoxic activity against six human solid tumour cell lines.</p> <p><i>Key steps:</i> (a) efficient construction of the THP:THF fragments through a stereoselective condensation between a pyranil aldehyde and an acetylene derivative; (b) palladium-catalysed coupling reaction between an alkyne and a terminal butenolide under Hovey's conditions.</p> <p>S. Takahashi, K. Maeda, S. Hirota and T. Nakata, <i>Org. Lett.</i>, 1999, 1, 2025.</p>	
<p>(-)-α-Kainic acid and (+)-α-Allokainic acid</p> <p><i>Biological activity:</i> neuroexcitatory properties.</p> <p><i>Key steps:</i> (a) from an alkyne precursor, a nickel-catalysed cyclisation and a palladium-catalysed rearrangement were used in the synthesis of (+)-α-allokainic acid; (b) from an allene precursor, a nickel-catalysed cyclisation was used in the synthesis of (-)-α-kainic acid.</p> <p>M. V. Chevliakov and J. Montgomery, <i>J. Am. Chem. Soc.</i>, 1999, 121, 11139.</p>	 <p style="text-align: center;">(-)-α-Kainic acid (+)-α-Allokainic acid</p>
<p>Korormicin</p> <p><i>Biological activity:</i> inhibits the growth of marine Gram-negative bacteria without affecting terrestrial species.</p> <p><i>Key steps:</i> (a) aldol condensation of a hydroxy aldehyde with an enolate of a Schiff base glycine ester to form the lactone moiety; (b) Stille coupling; (c) Sharpless epoxidation.</p> <p>H. Uehara, T. Oishi, K. Yoshikawa, K. Mochida and M. Hirama, <i>Tetrahedron Lett.</i>, 1999, 40, 8641.</p>	
<p>(-)-Lasubine(I)</p> <p><i>Biological activity:</i> not reported.</p> <p><i>Key steps:</i> (a) formation of an enantiopure planar chiral arylaldehyde tricarbonylchromium complex; (b) highly diastereoselective aza-Diels-Alder cycloaddition; (c) intramolecular radical cyclisation reactions to afford a quinolizidinone intermediate.</p> <p>H. Ratni and E. P. Kündig, <i>Org. Lett.</i>, 1999, 1, 1997.</p>	

<p>(+)-Laurencin</p> <p><i>Biological activity:</i> not reported.</p> <p><i>Key steps:</i> asymmetric alkylation-ring-closing metathesis approach to medium ring ethers.</p> <p>M. T. Crimmins and K. A. Emmitte, <i>Org. Lett.</i>, 1999, 1, 2029.</p>	
<p>Manoalide</p> <p><i>Biological activity:</i> (a) analgesic; (b) anti-inflammatory; (c) inhibition of phospholipase A₂ (PLA₂).</p> <p><i>Key steps:</i> enantioselective aldol condensation using a Ti(O<i>i</i>Pr)₄-(<i>R</i>)-(+)-BINOL complex.</p> <p>A. Soriente, M. De Rosa, A. Apicella, A. Scettri and G. Sodano, <i>Tetrahedron: Asymmetry</i>, 1999, 10, 4481.</p>	
<p>Mollamide</p> <p><i>Biological activity:</i> shows cytotoxicity against a range of cell lines with an IC₅₀ of 1 μg ml⁻¹ for murine leukaemia and 2.5 μg ml⁻¹ against human lung carcinoma.</p> <p><i>Key steps:</i> macrolactamisation.</p> <p>B. McKeever and G. Pattenden, <i>Tetrahedron Lett.</i>, 1999, 40, 9317.</p>	
<p>Nakijiquinone C</p> <p><i>Biological activity:</i> selective inhibitor of the Her-2/Neu Protooncogene.</p> <p><i>Key steps:</i> (a) reductive alkylation of an α,β-unsaturated Wieland-Miescher type enone with a benzyl halide; (b) Wittig reactions.</p> <p>P. Stahl and H. Waldmann, <i>Angew. Chem., Int. Ed.</i>, 1999, 38, 3710.</p>	
<p>(-)-Palitantine</p> <p><i>Biological activity:</i> metabolite isolated from <i>Penicillium palitans</i> that exhibits antifungal and antibiotic activities.</p> <p><i>Key steps:</i> (a) Sharpless asymmetric dihydroxylation of a dienylsilane; (b) oxidation of C-Si bond.</p> <p>R. Angelaud, O. Babot, T. Charvat and Y. Landais, <i>J. Org. Chem.</i>, 1999, 64, 9613.</p>	
<p>Puuphedione</p> <p><i>Biological activity:</i> antitumour activity against cell lines P-388, A-549, HT-29.</p> <p><i>Key steps:</i> several strategies were attempted.</p> <p>A. F. Barrero, E. J. Alvarez-Manzaneda, R. Chahboun, M. Cortés and V. Armstrong, <i>Tetrahedron</i>, 1999, 55, 15181.</p>	